Screening, clinical features and prognostic analysis of liver cirrhosis-related hepatocellular carcinoma

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Carr BI. Hepatocellular carcinoma: current management and further trends. Gastroenterology. 2004;127(5):S218–S224.
   PubMed Web of Science ®Google Scholar
• Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–474.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380.
   PubMed Web of Science ®Google Scholar
• Ministry of Health of the People’s Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma. J Clin Hepatol. 2011;27(11):1141–1159.
   Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–1917.
   PubMed Web of Science ®Google Scholar
• Becker-Assmann J, Fard-Aghaie MH, Kantas A, et al. Diagnostic and prognostic significance of α-fetoprotein in hepatocellular carcinoma. Chirurg. 2020;91(9):769–777.
   PubMed Web of Science ®Google Scholar
• Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006;101(3):524–532.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–118.
   PubMed Web of Science ®Google Scholar
• Liu C, Xiao GQ, Yan LN, et al. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol. 2013;19(11):1811–1819.
   PubMed Web of Science ®Google Scholar
• Abbasi A, Bhutto AR, Butt N, et al. Correlation of serum alpha fetoprotein and tumor size in hepatocellular carcinoma. J Pak Med Assoc. 2012;62(1):33–36.
   PubMed Web of Science ®Google Scholar
• Toyoda H, Kumada T, Tada T, et al. Tumor markers for hepatocellular carcinoma: simple and significant predictors of outcome in patients with HCC. Liver Cancer. 2015;4(2):126–136.
   PubMed Web of Science ®Google Scholar
• Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014;272(3):635–654.
   PubMed Web of Science ®Google Scholar
• Xu J, Liu C, Zhou L, et al. Distinctions between clinicopathological factors and prognosis of alpha-fetoprotein negative and positive hepatocellular carcinoma patients. Asian Pac J Cancer Prev. 2012;13(2):559–562.
   PubMedGoogle Scholar
• Hong YM, Yoon KT, Cho M, et al. A case of small hepatocellular carcinoma with an extensive lymph node metastasis. Clin Mol Hepatol. 2014;20(3):310–312.
   PubMedGoogle Scholar
• Lin MT, Wang CC, Cheng YF, et al. Comprehensive comparison of multiple-detector computed tomography and dynamic magnetic resonance imaging in the diagnosis of hepatocellular carcinoma with varying degrees of fibrosis. PLoS One. 2016;11(11):e0166157.
   PubMed Web of Science ®Google Scholar
• Di Martino M, Michele Anzidei M, Zaccagna F, et al. Qualitative analysis of small (≤2 cm) regenerative nodules, dysplastic nodules and well-differentiated HCCs with gadoxetic acid MRI. BMC Med Imaging. 2016;16(1):1–7.
   PubMed Web of Science ®Google Scholar
• Robert FH, Diego AA, Norbert K, et al. Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radio Graphics. 2008;28(3):747–769.
   Google Scholar
• Liu F, Luo L, Wei Y, et al. A functional NQO1 609C > T polymorphism and risk of hepatocellular carcinoma in a Chinese population. Tumor Biol. 2013;34(1):47–53. Epub 2012 Sep 13.
   PubMed Web of Science ®Google Scholar
• Duan CY, Zhang WL, Lu JF, et al. DNA repair gene XRCC3 Thr241Met polymorphism and hepatocellular carcinoma risk. Tumour Biol. 2013;34(5):2827–2834. Epub 2013 Jul 4.
   PubMedGoogle Scholar
• Cheng K, Zhao YJ, Liu L, et al. Tumor necrosis factor-α 238 G/A polymorphism and risk of hepatocellular carcinoma: evidence from a meta-analysis. Asian Pac J Cancer Prev. 2013;14(5):3275–3279.
   PubMedGoogle Scholar
• Luo J, Chen S, Wang J, et al. Genetic polymorphisms in complement receptor1 gene and its association with HBV-related liver disease: a case-control study. Gene. 2019;688:107–118.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022.
   PubMed Web of Science ®Google Scholar
• Cha DI, Song KD, Kang TW, et al. Small masses (≤3 cm) diagnosed as hepatocellular carcinoma on pre-treatment imaging: comparison of therapeutic outcomes between hepatic resection and radiofrequency ablation. Br J Radiol. 2020;93(1105):20190719.
   PubMed Web of Science ®Google Scholar
• Peng ZW, Lin XJ, Zhang YJ, et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology. 2012;262(3):1022–1033.
   PubMed Web of Science ®Google Scholar
• Liu W, Xu H, Ying X, et al. Radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) for patients with medium-to-large hepatocellular carcinoma: a retrospective analysis of long-term outcome. Med Sci Monit. 2020;26:e923263.
   PubMed Web of Science ®Google Scholar